317 related articles for article (PubMed ID: 23181222)
1. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases.
Litvinov D; Mahini H; Garelnabi M
N Am J Med Sci; 2012 Nov; 4(11):523-32. PubMed ID: 23181222
[TBL] [Abstract][Full Text] [Related]
2. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention.
Mackness MI; Durrington PN; Mackness B
Am J Cardiovasc Drugs; 2004; 4(4):211-7. PubMed ID: 15285696
[TBL] [Abstract][Full Text] [Related]
3. Paraoxonase, a cardioprotective enzyme: continuing issues.
Getz GS; Reardon CA
Curr Opin Lipidol; 2004 Jun; 15(3):261-7. PubMed ID: 15166781
[TBL] [Abstract][Full Text] [Related]
4. [The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis].
Tomás M; Latorre G; Sentí M; Marrugat J
Rev Esp Cardiol; 2004 Jun; 57(6):557-69. PubMed ID: 15225502
[TBL] [Abstract][Full Text] [Related]
5. The Role of Polyphenols in Modulating PON1 Activity Regarding Endothelial Dysfunction and Atherosclerosis.
Sirca TB; Mureșan ME; Pallag A; Marian E; Jurca T; Vicaș LG; Tunduc IP; Manole F; Ștefan L
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474211
[TBL] [Abstract][Full Text] [Related]
6. Paraoxonase and atherosclerosis.
Durrington PN; Mackness B; Mackness MI
Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):473-80. PubMed ID: 11304460
[TBL] [Abstract][Full Text] [Related]
7. Role of Paraoxonase1 in the Regulation of High-Density Lipoprotein Functionality and in Cardiovascular Protection.
Khalil A; Fulop T; Berrougui H
Antioxid Redox Signal; 2021 Jan; 34(3):191-200. PubMed ID: 31969002
[No Abstract] [Full Text] [Related]
8. Paraoxonase 1 and atherosclerosis.
Durrington PN; Bashir B; Soran H
Front Cardiovasc Med; 2023; 10():1065967. PubMed ID: 36873390
[TBL] [Abstract][Full Text] [Related]
9. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice.
Tward A; Xia YR; Wang XP; Shi YS; Park C; Castellani LW; Lusis AJ; Shih DM
Circulation; 2002 Jul; 106(4):484-90. PubMed ID: 12135950
[TBL] [Abstract][Full Text] [Related]
10. The role of 'paraoxonase-1 activity' as an antioxidant in coronary artery diseases.
Shekhanawar M; Shekhanawar SM; Krisnaswamy D; Indumati V; Satishkumar D; Vijay V; Rajeshwari T; Amareshwar M
J Clin Diagn Res; 2013 Jul; 7(7):1284-7. PubMed ID: 23998046
[TBL] [Abstract][Full Text] [Related]
11. Atherosclerosis and arteriosclerosis parameters in stroke patients associate with paraoxonase polymorphism and esterase activities.
Shenhar-Tsarfaty S; Waiskopf N; Ofek K; Shopin L; Usher S; Berliner S; Shapira I; Bornstein NM; Ritov Y; Soreq H; Ben Assayag E
Eur J Neurol; 2013 Jun; 20(6):891-8. PubMed ID: 23305304
[TBL] [Abstract][Full Text] [Related]
12. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity.
Jaouad L; Milochevitch C; Khalil A
Free Radic Res; 2003 Jan; 37(1):77-83. PubMed ID: 12653220
[TBL] [Abstract][Full Text] [Related]
13. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS
Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme.
Mahrooz A
Curr Clin Pharmacol; 2016; 11(4):259-264. PubMed ID: 27633038
[TBL] [Abstract][Full Text] [Related]
15. Paraoxonase and coronary heart disease.
Mackness MI; Mackness B; Durrington PN
Atheroscler Suppl; 2002 Dec; 3(4):49-55. PubMed ID: 12573363
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the role of paraoxonase gene polymorphism (Q192R) and paraoxonase activity in the susceptibility to atherosclerosis among lead-exposed workers.
Kamal M; Fathy MM; Taher E; Hasan M; Tolba M
Ann Saudi Med; 2011; 31(5):481-7. PubMed ID: 21911985
[TBL] [Abstract][Full Text] [Related]
17. Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: Genotypic and phenotypic evaluation.
Shokri Y; Variji A; Nosrati M; Khonakdar-Tarsi A; Kianmehr A; Kashi Z; Bahar A; Bagheri A; Mahrooz A
Diabetes Res Clin Pract; 2020 Mar; 161():108067. PubMed ID: 32044348
[TBL] [Abstract][Full Text] [Related]
18. Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.
Efrat M; Rosenblat M; Mahmood S; Vaya J; Aviram M
Atherosclerosis; 2009 Feb; 202(2):461-9. PubMed ID: 18585720
[TBL] [Abstract][Full Text] [Related]
19. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
Rosenblat M; Karry R; Aviram M
Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
[TBL] [Abstract][Full Text] [Related]
20. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice.
Rozenberg O; Shih DM; Aviram M
Atherosclerosis; 2005 Jul; 181(1):9-18. PubMed ID: 15939049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
